Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 11/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347376 | 0.87 | GAA (0.65) | RAB9ASMN1; SMN2NPC1GAAALDH1A1 | |
| SCHEMBL4438310 | 0.86 | ALDH1A1 (0.61) | RAB9ASMN1; SMN2NPC1GAAALDH1A1 | |
| SCHEMBL3640599 | 0.84 | DHODH (0.51) | RAB9ASMN1; SMN2NPC1GAAALDH1A1 | |
| SCHEMBL1347532 | 0.82 | ALDH1A1 (0.62) | RAB9ASMN1; SMN2GAAALDH1A1KDM4E | |
| SCHEMBL1344833 | 0.80 | MAPT (0.53) | RAB9ASMN1; SMN2GAAALDH1A1KDM4E | |
| SCHEMBL1346228 | 0.77 | GAA (0.83) | RAB9ASMN1; SMN2NPC1GAAALDH1A1 | |
| SCHEMBL13547676 | 0.74 | GAA (1.00) | RAB9ASMN1; SMN2NPC1GAAALDH1A1 | |
| SCHEMBL1346796 | 0.73 | POLB (0.54) | RAB9ASMN1; SMN2NPC1GAAALDH1A1 | |
| SCHEMBL1864184 | 0.72 | GAA (0.61) | RAB9ANPC1GAAALDH1A1KDM4E | |
| SCHEMBL19472826 | 0.71 | RAB9A (0.79) | RAB9ASMN1; SMN2NPC1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128156-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | FLT4, VEGFA, FLT1 | RAB9A 2350/4885SMN1; SMN2 4393/4885NPC1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.